F528, a novel anti-inflammation agent with the potential to modify the progression of chronic obstructive pulmonary disease ("COPD”), is undergoing preclinical studies as a potential first-line ...

Noble Capital initiated coverage of Gyre Therapeutics (GYRE) with an Outperform rating. Gyre is developing drugs for inflammatory diseases that ...

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria ...

Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

Of note, 75% participants used anti-fibrotic drug pirfenidone as concomitant medication in this trial. None of them used Nintedanib as concomitant medication. At final passage, P63+ progenitor cells ...

It’s been a little over 10 years since the antifibrotics pirfenidone [Esbriet] and nintedanib [Ofev] were approved by the FDA. I think providers have become more comfortable over time with the use of ...

Currently, patients with this disease only have two FDA-approved treatments — nintedanib (Ofev, Boehringer Ingelheim) and pirfenidone (Esbriet, Genentech) — both of which could use improvement ...

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

Dysbiosis is the condition of having imbalances in the microbial communities either in or on the body. Dysbiosis is associated with many diseases, such as inflammatory bowel disease and chronic ...

THE Los Angeles County wildfires in January 2025 had a notable impact on healthcare utilization, with emergency department (ED) visits decreasing by 9% while wildfire-associated visits spiked ...